The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

IGLL1  -  immunoglobulin lambda-like polypeptide 1

Homo sapiens

Synonyms: 14.1, AGM2, CD179 antigen-like family member B, CD179B, CD179b, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of IGLL1


Psychiatry related information on IGLL1

  • Louis Kiddie Schedule for Affective Disorders and Schizophrenia, each with a parent with BD, and 20 age-, gender-, and intelligence quotient-matched healthy control subjects (aged 14.1 +/- 2.8 years; 4 female) were scanned at 3 T. Most subjects were taking psychotropic medications [6].
  • VI during the ventilatory phase of the periodic breathing cycle increased progressively with increasing grades of associated arousals from Grade 0 (no arousal) (10.3 +/- 1.4 L/min) to Grade 1 (EEG arousal) (12.6 +/- 1.6 L/min) to Grade 2 (movement arousal) (14.1 +/- 1.6 L/min, p < 0.01) [7].
  • RESEARCH METHODS AND PROCEDURES: Obese adolescents [N = 61; age, 14.1 (+/-0.2) years; BMI, 33.9 (+/-0.7) kg/m(2)] completed assessments of body weight and height and self-esteem and a sentence-completion test eliciting thoughts and beliefs about exercise, eating, and appearance at the start and end of the camp (mean stay, 26 days) [8].
  • The adjusted odds ratios for reporting alcohol consumption and use of drugs at the last sexual encounter in this group compared with the telephone respondents were 3.7 (2.1, 6.6) and 14.1 (5.7, 34.5) respectively [9].
  • During wakefulness, the volume threshold (at eupneic fR) averaged 969 +/- 94 ml or 1.3-1.4 times the average eupneic tidal volume; the frequency threshold (at eupneic VT was 14.1 +/- 0.7 min-1 or 1.2 times the average eupneic frequency [10].

High impact information on IGLL1

  • In addition, as compared with placebo, carvedilol therapy was accompanied by a 27 percent reduction in the risk of hospitalization for cardiovascular causes (19.6 percent vs. 14.1 percent, P = 0.036), as well as a 38 percent reduction in the combined risk of hospitalization or death (24.6 percent vs, 15.8 percent, P < 0.001) [11].
  • The respective reductions in low-density lipoprotein (LDL) cholesterol were 14.1 percent in the sitostanol group and 1.1 percent in the control group [12].
  • Seventeen children and young adults (mean [+/- SD] age, 14.1 +/- 3.7 years) undergoing regular peritoneal dialysis were randomly assigned to treatment with either aluminum hydroxide (n = 7; maximal dose, 30 mg per kilogram of body weight per day) or calcium carbonate (n = 10; dose range, 2.5 to 12 g per day, according to serum phosphorus levels) [13].
  • There were also increases after 12 weeks in the mean total lymphocyte count (from 0.8 to 1.2 x 10(9) per liter) and the mean hemoglobin level (from 12.9 to 14.1 g per deciliter) (both P less than 0.01) [14].
  • The treatment arrested labor for at least three days in 61 per cent of patients; gestation was extended by 14.1 +/- 1.1 weeks (mean +/- S.E.M.) in infants with the earliest gestational age at treatment (20 to 25 weeks) and by 2.3 +/- 0.7 weeks in those with the latest gestational age (36 to 37 weeks) [15].

Chemical compound and disease context of IGLL1

  • VLDL triglyceride PR also fell after weight reduction (56.6 +/- 39.0 vs. 28.6 +/- 23.1 mg/kg per h, P less than 0.05), as did VLDL apo B PR (47.9 +/- 41.4 vs. 19.0 +/- 14.1 mg/kg per d, P less than 0.05) [16].
  • In contrast, propranolol caused a significant decrease in the pressure of esophageal varices (from 14.1 +/- 5 mm Hg to 11.3 +/- 4.4 mm Hg; p less than 0.0002) [17].
  • The fraction of administered methionine undergoing remethylation was lower in patients with cirrhosis (7.6 +/- 1.5 vs. 14.1 +/- 1.1%, P <.005) [18].
  • Pertussis toxin catalyzes incorporation of 20.2 pmol of ADP-ribose/mg of protein into approximately 40-kDa protein(s) in human neutrophil membranes compared with 14.1 pmol/mg in bovine brain membranes [19].
  • Serum angiotensin converting enzyme was lower in Crohn's disease (14.1 +/- 5.1) than in controls (25.2 +/- 4.7) (p less than 0.001) [20].

Biological context of IGLL1


Anatomical context of IGLL1

  • Analysis of a panel of 26 hematopoietic cell lines reveals that expression of 14.1/16.1 is limited to pre-B cells and one B-cell line, which, like the pre-B cells, is surface immunoglobulin negative [25].
  • To precisely map the location of the human IGLL genes in relation to each other and to the human IGL gene locus, at 22q11.1-2, a somatic cell hybrid panel and pulsed field gel electrophoresis (PFGE) were used [1].
  • The 14.1 surrogate light chain protein is expressed on human pre-B lymphocytes in association with Vpre-B and the mu Ig heavy chain to form the pre-B receptor [22].
  • Compliance was significantly lower in the common carotid artery in symptomatic and asymptomatic women with polycystic ovaries than in the controls (10.7, 14.1, and 19.2 %mm Hg(-1)x10(-2), respectively) [26].
  • The half-life in the bone marrow was 14.1 h [27].

Associations of IGLL1 with chemical compounds

  • PCOP, lower in the pre-eclamptics (16.1 +/- SD 0.6 mm Hg vs 19.9 +/- 0.7 mm Hg in controls, p less than 0.001) before the start of parenteral infusions, decreased in both groups and at delivery it was 14.1 +/- 0.5 mm Hg in the hypertensive women and 17.2 +/- 0.6 mm Hg in the controls p less than 0.001) [28].
  • Total procainamide clearance (16.2, 14.1, and 13.7 ml/min/kg) did not differ significantly between the three trials, nor was there a significant change in area under the serum concentration curve for N-acetylprocainamide, the major metabolite [29].
  • High test species subjects receiving tetracycline exhibited the best ratio of gaining to losing sites (16.2), followed by low test species subjects receiving Augmentin (14.1) [30].
  • The free energies of activation for the proton exchange were measured by the Forsén-Hoffman method as DeltaG([double dagger])298= 16.2 +/- 0.6 kcal mol(-1) as an average for 4a-c in CD2Cl2, acetone-d6, and methanol-d4, and 14.1 +/- 0.6 kcal mol(-1) for in 4c acetone/D2O [31].
  • After 4 days of treatment the mean daily doses of enprofylline and theophylline, which were 14.1 and 16.2 mg/kg/day, produced mean plasma concentrations of 4.9 and 12.7 micrograms/ml, respectively [32].

Other interactions of IGLL1

  • Physical location of the human immunoglobulin lambda-like genes, 14.1, 16.1, and 16.2 [1].
  • Immunoprecipitation of immunoglobulin mu-chain from these pre-B cells with anti-immunoglobulin mu antibody coprecipitates a 22-kDa protein, which is a candidate for the human immunoglobulin omega light-chain protein and may be the protein product of the 14.1/16.1 genes [25].
  • Antisera raised against a peptide whose sequence was predicted from the 14.1 cDNA sequence identifies a 22-kDa protein in human pre-B cells [25].
  • B cell precursors transiently express a pre-B cell receptor complex consisting of a rearranged mu heavy chain, a surrogate light chain composed of lambda5/14.1 and VpreB, and the immunoglobulin (Ig)-associated signal transducing chains, Igalpha and Igbeta [2].
  • We have used RNase protection analysis to localize the 5' major transcriptional start site and rapid amplification of 5' cDNA ends to identify multiple start sites within the TATA-less, GC-rich 14.1 promoter [22].

Analytical, diagnostic and therapeutic context of IGLL1

  • Median progression-free survival was 5.7 months (95% CI, 1.9 to 9.6 months) versus 14.1 months (95% CI, 12.0 to 16.2 months; P<.001) and overall survival was 12.0 months (95% CI, 8.0 to 15.6 months) versus 36.7 months (95% CI, 25.2 to 48.2 months; P<.001) for cases and controls, respectively [33].
  • To examine the expression of the surrogate light-chain components CD179a and CD179b in precursor B-cell lymphoblastic lymphoma, we analyzed tissue sections using immunohistochemistry techniques [3].
  • Among a number of monoclonal antibodies for the surrogate light chains, VpreB8 and SL11 were found to detect CD179a and CD179b, respectively, in acetone-fixed fresh frozen sections [3].
  • Furthermore, other pediatric tumors that must be included in a differential diagnosis of precursor B-cell lymphoblastic lymphoma, including precursor T-cell lymphoblastic lymphoma, extramedullary myeloid tumors, and Ewing sarcoma, were also negative for both CD179a and CD179b [3].
  • In 4 patients, data posthemodialysis and later during CAPD revealed that PRA increased from 0.9 +/- 0.3 to 14.1 +/- 4.6 and PA increased from 3.4 +/- 0.3 to 67.4 +/- 24.9 on CAPD (p less than 0.05) [34].


  1. Physical location of the human immunoglobulin lambda-like genes, 14.1, 16.1, and 16.2. Bauer, T.R., McDermid, H.E., Budarf, M.L., Van Keuren, M.L., Blomberg, B.B. Immunogenetics (1993) [Pubmed]
  2. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. Minegishi, Y., Coustan-Smith, E., Wang, Y.H., Cooper, M.D., Campana, D., Conley, M.E. J. Exp. Med. (1998) [Pubmed]
  3. Diagnostic importance of CD179a/b as markers of precursor B-cell lymphoblastic lymphoma. Kiyokawa, N., Sekino, T., Matsui, T., Takenouchi, H., Mimori, K., Tang, W.R., Matsui, J., Taguchi, T., Katagiri, Y.U., Okita, H., Matsuo, Y., Karasuyama, H., Fujimoto, J. Mod. Pathol. (2004) [Pubmed]
  4. Severe bradycardia during spinal and epidural anesthesia recorded by an anesthesia information management system. Lesser, J.B., Sanborn, K.V., Valskys, R., Kuroda, M. Anesthesiology (2003) [Pubmed]
  5. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Abrams, R.A., Grochow, L.B., Chakravarthy, A., Sohn, T.A., Zahurak, M.L., Haulk, T.L., Ord, S., Hruban, R.H., Lillemoe, K.D., Pitt, H.A., Cameron, J.L., Yeo, C.J. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  6. Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Chang, K., Barnea-Goraly, N., Karchemskiy, A., Simeonova, D.I., Barnes, P., Ketter, T., Reiss, A.L. Biol. Psychiatry (2005) [Pubmed]
  7. Interaction of hyperventilation and arousal in the pathogenesis of idiopathic central sleep apnea. Xie, A., Wong, B., Phillipson, E.A., Slutsky, A.S., Bradley, T.D. Am. J. Respir. Crit. Care Med. (1994) [Pubmed]
  8. Cognitive change in obese adolescents losing weight. Barton, S.B., Walker, L.L., Lambert, G., Gately, P.J., Hill, A.J. Obes. Res. (2004) [Pubmed]
  9. AIDS and behavioural risk factors in women in inner city Baltimore: a comparison of telephone and face to face surveys. Nebot, M., Celentano, D.D., Burwell, L., Davis, A., Davis, M., Polacsek, M., Santelli, J. Journal of epidemiology and community health. (1994) [Pubmed]
  10. Frequency and volume thresholds for inhibition of inspiratory motor output during mechanical ventilation. Manchanda, S., Leevers, A.M., Wilson, C.R., Simon, P.M., Skatrud, J.B., Dempsey, J.A. Respiration physiology. (1996) [Pubmed]
  11. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. N. Engl. J. Med. (1996) [Pubmed]
  12. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. Miettinen, T.A., Puska, P., Gylling, H., Vanhanen, H., Vartiainen, E. N. Engl. J. Med. (1995) [Pubmed]
  13. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky, I.B., Foley, J., Nelson, P., Goodman, W.G. N. Engl. J. Med. (1991) [Pubmed]
  14. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. Cooley, T.P., Kunches, L.M., Saunders, C.A., Ritter, J.K., Perkins, C.J., McLaren, C., McCaffrey, R.P., Liebman, H.A. N. Engl. J. Med. (1990) [Pubmed]
  15. The cost effectiveness of stopping preterm labor with beta-adrenergic treatment. Korenbrot, C.C., Aalto, L.H., Laros, R.K. N. Engl. J. Med. (1984) [Pubmed]
  16. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. Ginsberg, H.N., Le, N.A., Gibson, J.C. J. Clin. Invest. (1985) [Pubmed]
  17. Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Feu, F., Bordas, J.M., Garcia-Pagán, J.C., Bosch, J., Rodés, J. Hepatology (1991) [Pubmed]
  18. Remethylation and transsulfuration of methionine in cirrhosis: studies with L-[H3-methyl-1-C]methionine. Russmann, S., Junker, E., Lauterburg, B.H. Hepatology (2002) [Pubmed]
  19. Immunochemical evidence for a novel pertussis toxin substrate in human neutrophils. Gierschik, P., Falloon, J., Milligan, G., Pines, M., Gallin, J.I., Spiegel, A. J. Biol. Chem. (1986) [Pubmed]
  20. Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Bonniere, P., Wallaert, B., Cortot, A., Marchandise, X., Riou, Y., Tonnel, A.B., Colombel, J.F., Voisin, C., Paris, J.C. Gut (1986) [Pubmed]
  21. Identification of three new Ig lambda-like genes in man. Chang, H., Dmitrovsky, E., Hieter, P.A., Mitchell, K., Leder, P., Turoczi, L., Kirsch, I.R., Hollis, G.F. J. Exp. Med. (1986) [Pubmed]
  22. The 14.1 surrogate light chain promoter has lineage- and stage-restricted activity. Donohoe, M.E., Blomberg, B.B. J. Immunol. (1997) [Pubmed]
  23. Isolation of early immunoglobulin lambda-like gene transcripts in human fetal liver. Schiff, C., Milili, M., Fougereau, M. Eur. J. Immunol. (1989) [Pubmed]
  24. Organization and expression of the lambda-like genes that contribute to the mu-psi light chain complex in human pre-B cells. Bossy, D., Milili, M., Zucman, J., Thomas, G., Fougereau, M., Schiff, C. Int. Immunol. (1991) [Pubmed]
  25. Immunoglobulin lambda light-chain-related genes 14.1 and 16.1 are expressed in pre-B cells and may encode the human immunoglobulin omega light-chain protein. Hollis, G.F., Evans, R.J., Stafford-Hollis, J.M., Korsmeyer, S.J., McKearn, J.P. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  26. Impaired carotid viscoelastic properties in women with polycystic ovaries. Lakhani, K., Seifalian, A.M., Hardiman, P. Circulation (2002) [Pubmed]
  27. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Mistry, P.K., Wraight, E.P., Cox, T.M. Lancet (1996) [Pubmed]
  28. Serial plasma oncotic pressure levels and echoencephalography during and after delivery in severe pre-eclampsia. Zinaman, M., Rubin, J., Lindheimer, M.D. Lancet (1985) [Pubmed]
  29. Metoprolol or propranolol does not alter the kinetics of procainamide. Ochs, H.R., Carstens, G., Roberts, G.M., Greenblatt, D.J. J. Cardiovasc. Pharmacol. (1983) [Pubmed]
  30. Response to periodontal therapy in patients with high or low levels of P. gingivalis, P. intermedia, P. nigrescens and B. forsythus. Haffajee, A.D., Socransky, S.S., Dibart, S., Kent, R.L. Journal of clinical periodontology. (1996) [Pubmed]
  31. 1H-1,3-diazepines, 5H-1,3-diazepines, 1,3-diazepinones, and 2,4-diazabicyclo[3.2.0]heptenes. Reisinger, A., Koch, R., Bernhardt, P.V., Wentrup, C. Org. Biomol. Chem. (2004) [Pubmed]
  32. Enprofylline and theophylline slow-eroding tablets in the treatment of asthma: a comparison. Laursen, L.C., Eriksson, G., Weeke, B. Respiration; international review of thoracic diseases. (1986) [Pubmed]
  33. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. Hess, V., A'Hern, R., Nasiri, N., King, D.M., Blake, P.R., Barton, D.P., Shepherd, J.H., Ind, T., Bridges, J., Harrington, K., Kaye, S.B., Gore, M.E. J. Clin. Oncol. (2004) [Pubmed]
  34. Increased levels of plasma renin, aldosterone, catecholamines and vasopressin in chronic ambulatory peritoneal dialysis (CAPD) patients. Zabetakis, P.M., Kumar, D.N., Gleim, G.W., Gardenswartz, M.H., Agrawal, M., Robinson, A.G., Michelis, M.F. Clin. Nephrol. (1987) [Pubmed]
WikiGenes - Universities